Biological agents, including TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, have demonstrated significant efficacy in the treatment of psoriasis (Ohtsuki et al., 2019). The gene discussed is IL17A; the disease is psoriasis.